FDA Debars Ohio Oncologist for Misbranded Drugs

January 8, 2019

The FDA issued an order to debar an Ohio oncologist from purchasing and receiving unapproved drugs from a Canadian distributor.

Ranjan Bhandari was convicted of a misdemeanor in 2013 for buying misbranded prescription drugs between 2006 and 2008, including Zometa (zoledronic acid), a high blood calcium treatment; Gemzar (gemcitabine), an oncology treatment; and Aranesp (darbepoetin alfa), a bone marrow stimulant.

Bhandari is debarred for three years from providing services to any person with an approved or pending drug product application.

View today's stories